Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723416 | 0.76 | BCHE (0.34) | GAAMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL9052010 | 0.72 | ALDH1A1 (0.38) | GAAMAPTKDM4EL3MBTL1CHRNA1 | |
| SCHEMBL9319280 | 0.71 | ALDH1A1 (0.41) | GAAMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL763408 | 0.69 | ALDH1A1 (0.41) | GAAMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL5048184 | 0.69 | HRH3 (0.50) | GAAMAPTKDM4EL3MBTL1CHRNA1 | |
| SCHEMBL25325647 | 0.68 | GAA (0.46) | GAAMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL12697280 | 0.68 | GAA (0.46) | GAAMAPTKDM4EL3MBTL1CHRNA1 | |
| SCHEMBL13040797 | 0.67 | ALDH1A1 (0.47) | GAAMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL14080397 | 0.67 | GAA (0.33) | GAAMAPTKDM4EL3MBTL1CHRNA1 | |
| Hydrochloric Acid SCHEMBL9281543 | 0.67 | GAA (0.44) | GAAMAPTKDM4EL3MBTL1CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638010-B1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE DERIVATIVES STARTING FROM N-(2,2-DIFLUOROETHYL)PROP-2-EN-1-AMINE | BAYER IP GMBH (DE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2638010-B1 | METHOD FOR PREPARING 2,2-DIFLUOROETHYLAMINE DERIVATIVES STARTING FROM N-(2,2-DIFLUOROETHYL)PROP-2-EN-1-AMINE | BAYER IP GMBH (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-8586756-B2 | Process for the preparation of 2,2-difluoroethylamine derivatives starting from N-(2,2-difluoroethyl)prop-2-en-1-amine | BAYER CROPSCIENCE AG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-8586756-B2 | Process for the preparation of 2,2-difluoroethylamine derivatives starting from N-(2,2-difluoroethyl)prop-2-en-1-amine | BAYER CROPSCIENCE AG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-8586756-B2 | Process for the preparation of 2,2-difluoroethylamine derivatives starting from N-(2,2-difluoroethyl)prop-2-en-1-amine | BAYER CROPSCIENCE AG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120123130-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE DERIVATIVES STARTING FROM N-(2,2-DIFLUOROETHYL)PROP-2-EN-1-AMINE | BAYER CROPSCIENCE AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120123130-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE DERIVATIVES STARTING FROM N-(2,2-DIFLUOROETHYL)PROP-2-EN-1-AMINE | BAYER CROPSCIENCE AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120123130-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE DERIVATIVES STARTING FROM N-(2,2-DIFLUOROETHYL)PROP-2-EN-1-AMINE | BAYER CROPSCIENCE AG (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123130-A1 | PROCESS FOR THE PREPARATION OF 2,2-DIFLUOROETHYLAMINE DERIVATIVES STARTING FROM N-(2,2-DIFLUOROETHYL)PROP-2-EN-1-AMINE | AFF2, AFF1, AFF4 | GAA 1522/4885MAPT 2934/4885KDM4E 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.